Export

Delamanid
Essential medicine status
Section:
6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines
ATC codes: J04AK06
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis ICD11 code: ML32.00
INN
Delamanid
Medicine type
Chemical agent
List type
Complementary
Additional notes
Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
Formulations
Oral > Solid: 50 mg tablet ; 25 mg tablet (dispersible) (EMLc)
EML status history
First added in 2015 (TRS 994)
Changed in 2017 (TRS 1006)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Delamanid
DrugBank
Delamanid
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the removal of the age restrictions from the listing of delamanid on the EML and EMLc, consistent with the recommendations for use of delamanid in current WHO guidelines for management of tuberculosis in children and adolescents.